Efficacy of Dapagliflozin on Recurrence After Catheter Ablation for Atrial Fibrillation
- Sponsor
- Beijing Anzhen Hospital
- Study ID
- NCT06433479
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 80 Years
- Healthy Volunteers
- Not accepted
Interventions
- Dapagliflozin 10 mg per day for 3 months after initial catheter ablation — DRUGDapagliflozin 10 mg per day for 3 months after initial catheter ablation
Study Details
This is a single-center, parallel-group, randomized, open-label trial evaluating the effect of 3-month treatment with dapagliflozin 10mg once daily on the recurrence of atrial fibrillation after catheter ablation for atrial fibrillation in patients without diabetes, heart failure, or chronic kidney disease.
Key Dates
- Start date
- Jul 15, 2024
- Status verified
- Jul 2025
- Primary completion
- Jul 1, 2025
- Completion
- Jul 1, 2025
Study Design
- Enrollment
- 200 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: DapagliflozinDapagliflozin 10 mg per day for 3 months after initial catheter ablation
- No Intervention: ControlNo intervention
Primary Outcome Measure
Atrial fibrillation burden at 3 months after ablation [ Time Frame: 3 months ]
Related Studies
- Identification of Genomic Predictors of Adverse Events After Cardiac SurgeryRecruiting · Brigham and Women's Hospital · Boston, Massachusetts
- Minocycline Plus Amiodarone Versus Amiodarone Alone for the Prevention of Atrial Fibrillation After Cardiac SurgeryPHASE2 · Not Yet Recruiting · Baystate Medical Center · Melrose, Massachusetts
- Pharmacogenetic Study of Antiarrhythmic Drugs for Atrial FibrillationPHASE4 · Recruiting · University of Illinois at Chicago · Chicago, Illinois
- Left Atrial Appendage Occlusion Registry (LAAO Registry)Recruiting · American College of Cardiology · Washington D.C., District of Columbia